drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB04844 | DB13074 | 843 | 877 | [
"DDInter1778",
"DDInter1110"
] | Tetrabenazine | Macimorelin | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
843,
25,
877
]
],
[
[
843,
62,
112
],
[
112,
23,
877
]
],
[
[
843,
24,
913
],
[
913,
24,
877
]
],
[
[
843,
1,
479
],
[
479,
24,
... | [
[
[
"Tetrabenazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Tetrabenazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Me... | Tetrabenazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide ... |
DB06704 | DB11627 | 247 | 1,367 | [
"DDInter952",
"DDInter860"
] | Iobenguane (I-131) | Hepatitis B Vaccine (Recombinant) | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
247,
24,
1367
]
],
[
[
247,
7,
6952
],
[
6952,
46,
77
],
[
77,
24,
1367
]
],
[
[
247,
18,
7359
],
[
7359,
57,
147
],
[
147,
24,
... | [
[
[
"Iobenguane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Iobenguane",
"{u} (Compound) upregulates {v} (Gene)",
"MCOLN1"
],
[
"MCOLN1",
"{u} (Gene)... | Iobenguane may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Iobenguane (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken... |
DB00065 | DB00445 | 581 | 322 | [
"DDInter923",
"DDInter655"
] | Infliximab | Epirubicin | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Major | 2 | [
[
[
581,
25,
322
]
],
[
[
581,
24,
112
],
[
112,
62,
322
]
],
[
[
581,
25,
1307
],
[
1307,
62,
322
]
],
[
[
581,
64,
1648
],
[
1648,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Epirubicin
Infliximab may lead to a major life threatening interaction when taken with Melphalan and Melphalan may caus... |
DB00261 | DB01591 | 702 | 667 | [
"DDInter93",
"DDInter1696"
] | Anagrelide | Solifenacin | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Major | 2 | [
[
[
702,
25,
667
]
],
[
[
702,
21,
28743
],
[
28743,
60,
667
]
],
[
[
702,
23,
112
],
[
112,
23,
667
]
],
[
[
702,
25,
774
],
[
774,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Solifenacin"
]
],
[
[
"Anagrelide",
"{u} (Compound) causes {v} (Side Effect)",
"Atrial fibrillation"
],
[
"Atrial fibrillation",
"{u} (Side Effect) i... | Anagrelide (Compound) causes Atrial fibrillation (Side Effect) and Atrial fibrillation (Side Effect) is caused by Solifenacin (Compound)
Anagrelide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects ... |
DB00238 | DB11703 | 188 | 405 | [
"DDInter1285",
"DDInter9"
] | Nevirapine | Acalabrutinib | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
188,
24,
405
]
],
[
[
188,
63,
1324
],
[
1324,
24,
405
]
],
[
[
188,
23,
1101
],
[
1101,
24,
405
]
],
[
[
188,
24,
951
],
[
951,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
... | Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Nevirapine may cause a minor interaction that can limit clinical effects when taken with Bexarotene and B... |
DB01234 | DB11979 | 1,220 | 1,320 | [
"DDInter513",
"DDInter625"
] | Dexamethasone | Elagolix | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1220,
24,
1320
]
],
[
[
1220,
62,
168
],
[
168,
23,
1320
]
],
[
[
1220,
23,
271
],
[
271,
23,
1320
]
],
[
[
1220,
24,
1297
],
[
1297,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
... | Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegr... |
DB00344 | DB05381 | 1,302 | 172 | [
"DDInter1543",
"DDInter863"
] | Protriptyline | Histamine | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | A depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter. | Moderate | 1 | [
[
[
1302,
24,
172
]
],
[
[
1302,
24,
1264
],
[
1264,
24,
172
]
],
[
[
1302,
63,
1242
],
[
1242,
24,
172
]
],
[
[
1302,
40,
413
],
[
413,
... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histamine"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Histamine
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetiriz... |
DB08875 | DB09020 | 1,618 | 28 | [
"DDInter262",
"DDInter212"
] | Cabozantinib | Bisacodyl | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
1618,
24,
28
]
],
[
[
1618,
64,
739
],
[
739,
24,
28
]
],
[
[
1618,
25,
938
],
[
938,
63,
28
]
],
[
[
1618,
63,
355
],
[
355,
24... | [
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
],
[
"Lomef... | Cabozantinib may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Cabozantinib may lead to a major life threatening interaction when taken with Pitolisant and Pitolisant may cause a modera... |
DB00696 | DB01254 | 826 | 1,213 | [
"DDInter665",
"DDInter484"
] | Ergotamine | Dasatinib | A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders. | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
826,
24,
1213
]
],
[
[
826,
6,
4973
],
[
4973,
45,
1213
]
],
[
[
826,
21,
29118
],
[
29118,
60,
1213
]
],
[
[
826,
24,
1619
],
[
1619,... | [
[
[
"Ergotamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Ergotamine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Ergotamine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dasatinib (Compound)
Ergotamine (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Dasatinib (Compound)
Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucap... |
DB00580 | DB09030 | 311 | 840 | [
"DDInter1910",
"DDInter1945"
] | Valdecoxib | Vorapaxar | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Moderate | 1 | [
[
[
311,
24,
840
]
],
[
[
311,
24,
885
],
[
885,
24,
840
]
],
[
[
311,
24,
1017
],
[
1017,
63,
840
]
],
[
[
311,
63,
1061
],
[
1061,
... | [
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
... | Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lor... |
DB00099 | DB09073 | 440 | 951 | [
"DDInter735",
"DDInter1379"
] | Filgrastim | Palbociclib | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Moderate | 1 | [
[
[
440,
24,
951
]
],
[
[
440,
24,
134
],
[
134,
24,
951
]
],
[
[
440,
24,
405
],
[
405,
63,
951
]
],
[
[
440,
63,
599
],
[
599,
24,... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib and ... |
DB00902 | DB01067 | 104 | 959 | [
"DDInter1168",
"DDInter826"
] | Methdilazine | Glipizide | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
104,
24,
959
]
],
[
[
104,
63,
245
],
[
245,
40,
959
]
],
[
[
104,
24,
1411
],
[
1411,
1,
959
]
],
[
[
104,
24,
1551
],
[
1551,
... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Comp... |
DB01319 | DB08896 | 34 | 292 | [
"DDInter777",
"DDInter1576"
] | Fosamprenavir | Regorafenib | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Moderate | 1 | [
[
[
34,
24,
292
]
],
[
[
34,
6,
8374
],
[
8374,
45,
292
]
],
[
[
34,
21,
28890
],
[
28890,
60,
292
]
],
[
[
34,
24,
549
],
[
549,
23... | [
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
]
],
[
[
"Fosamprenavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Comp... | Fosamprenavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Regorafenib (Compound)
Fosamprenavir (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Regorafenib (Compound)
Fosamprenavir may cause a moderate interaction that could exacerbate diseases ... |
DB00029 | DB00945 | 25 | 1,479 | [
"DDInter99",
"DDInter20"
] | Anistreplase | Acetylsalicylic acid | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl gro... | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Moderate | 1 | [
[
[
25,
24,
1479
]
],
[
[
25,
24,
1338
],
[
1338,
24,
1479
]
],
[
[
25,
23,
297
],
[
297,
62,
1479
]
],
[
[
25,
24,
557
],
[
557,
63... | [
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic ... | Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid
Anistreplase may cause a minor interaction that can limit clinical effects when taken ... |
DB00712 | DB01234 | 1,274 | 1,220 | [
"DDInter763",
"DDInter513"
] | Flurbiprofen | Dexamethasone | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
1274,
24,
1220
]
],
[
[
1274,
63,
870
],
[
870,
1,
1220
]
],
[
[
1274,
63,
175
],
[
175,
40,
1220
]
],
[
[
1274,
24,
167
],
[
167,
... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles... |
DB00501 | DB01218 | 752 | 1,493 | [
"DDInter380",
"DDInter852"
] | Cimetidine | Halofantrine | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Major | 2 | [
[
[
752,
25,
1493
]
],
[
[
752,
6,
3486
],
[
3486,
45,
1493
]
],
[
[
752,
21,
28809
],
[
28809,
60,
1493
]
],
[
[
752,
24,
211
],
[
211,
... | [
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Halof... | Cimetidine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Halofantrine (Compound)
Cimetidine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Halofantrine (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and... |
DB01132 | DB09389 | 1,130 | 517 | [
"DDInter1472",
"DDInter1315"
] | Pioglitazone | Norgestrel | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Minor | 0 | [
[
[
1130,
23,
517
]
],
[
[
1130,
24,
159
],
[
159,
63,
517
]
],
[
[
1130,
24,
1254
],
[
1254,
24,
517
]
],
[
[
1130,
63,
629
],
[
629,
... | [
[
[
"Pioglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norgestrel"
]
],
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
... | Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glu... |
DB06626 | DB14575 | 263 | 733 | [
"DDInter147",
"DDInter674"
] | Axitinib | Eslicarbazepine | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
263,
24,
733
]
],
[
[
263,
63,
1101
],
[
1101,
23,
733
]
],
[
[
263,
24,
351
],
[
351,
24,
733
]
],
[
[
263,
25,
129
],
[
129,
2... | [
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Eslicarbazepine
Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribocic... |
DB01115 | DB01240 | 336 | 885 | [
"DDInter1291",
"DDInter657"
] | Nifedipine | Epoprostenol | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
336,
24,
885
]
],
[
[
336,
63,
1061
],
[
1061,
1,
885
]
],
[
[
336,
6,
6017
],
[
6017,
45,
885
]
],
[
[
336,
10,
11573
],
[
11573,
... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Nifedipine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Epoprostenol (Compound)
Nifedipine (Compound) palliates systemic scleroderma (Dise... |
DB00477 | DB06203 | 216 | 1,002 | [
"DDInter363",
"DDInter51"
] | Chlorpromazine | Alogliptin | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
216,
24,
1002
]
],
[
[
216,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
216,
6,
12523
],
[
12523,
45,
1002
]
],
[
[
216,
21,
28778
],
[
2877... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],... | Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Chlorpromazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Alogliptin (Compound)
Chlorpromazine (Compound) causes Anaphylactic shock (Sid... |
DB00396 | DB01276 | 989 | 123 | [
"DDInter1529",
"DDInter706"
] | Progesterone | Exenatide | Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss. Progesterone is used in var... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
989,
24,
123
]
],
[
[
989,
1,
984
],
[
984,
63,
123
]
],
[
[
989,
24,
1476
],
[
1476,
63,
123
]
],
[
[
989,
1,
443
],
[
443,
24,... | [
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Progesterone",
"{u} (Compound) resembles {v} (Compound)",
"Danazol"
],
[
"Danazol",
"{u} may cause a moderate i... | Progesterone (Compound) resembles Danazol (Compound) and Danazol may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could ex... |
DB00851 | DB08903 | 611 | 996 | [
"DDInter463",
"DDInter170"
] | Dacarbazine | Bedaquiline | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Moderate | 1 | [
[
[
611,
24,
996
]
],
[
[
611,
24,
713
],
[
713,
63,
996
]
],
[
[
611,
63,
372
],
[
372,
24,
996
]
],
[
[
611,
24,
1686
],
[
1686,
2... | [
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]... | Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Clof... |
DB00468 | DB11057 | 1,424 | 720 | [
"DDInter1557",
"DDInter1223"
] | Quinine | Mineral oil | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
1424,
24,
720
]
],
[
[
1424,
24,
927
],
[
927,
63,
720
]
],
[
[
1424,
24,
1151
],
[
1151,
24,
720
]
],
[
[
1424,
25,
1069
],
[
1069,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib ... |
DB00039 | DB09330 | 1,253 | 985 | [
"DDInter1380",
"DDInter1352"
] | Palifermin | Osimertinib | Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
1253,
24,
985
]
],
[
[
1253,
24,
168
],
[
168,
23,
985
]
],
[
[
1253,
24,
134
],
[
134,
24,
985
]
],
[
[
1253,
24,
119
],
[
119,
... | [
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinore... |
DB00843 | DB00857 | 479 | 1,387 | [
"DDInter583",
"DDInter1768"
] | Donepezil | Terbinafine | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epox... | Minor | 0 | [
[
[
479,
23,
1387
]
],
[
[
479,
6,
8374
],
[
8374,
45,
1387
]
],
[
[
479,
7,
3361
],
[
3361,
46,
1387
]
],
[
[
479,
18,
10599
],
[
10599,
... | [
[
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Terbinafine"
]
],
[
[
"Donepezil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Donepezil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Terbinafine (Compound)
Donepezil (Compound) upregulates NFIL3 (Gene) and NFIL3 (Gene) is upregulated by Terbinafine (Compound)
Donepezil (Compound) downregulates PARP2 (Gene) and PARP2 (Gene) is downregulated by Terbinafine (Compound)
Donepezil (Com... |
DB01246 | DB14575 | 820 | 733 | [
"DDInter45",
"DDInter674"
] | Alimemazine | Eslicarbazepine | A phenothiazine derivative that is used as an antipruritic. | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
820,
24,
733
]
],
[
[
820,
74,
1264
],
[
1264,
24,
733
]
],
[
[
820,
63,
272
],
[
272,
24,
733
]
],
[
[
820,
24,
1491
],
[
1491,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when ... | Alimemazine (Compound) resembles Doxepin (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Alimemazine may cause a moderate interaction that could ... |
DB00963 | DB06209 | 1,263 | 256 | [
"DDInter241",
"DDInter1508"
] | Bromfenac | Prasugrel | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool f... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Major | 2 | [
[
[
1263,
25,
256
]
],
[
[
1263,
21,
28847
],
[
28847,
60,
256
]
],
[
[
1263,
62,
752
],
[
752,
23,
256
]
],
[
[
1263,
63,
305
],
[
305,
... | [
[
[
"Bromfenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
],
[
[
"Bromfenac",
"{u} (Compound) causes {v} (Side Effect)",
"Eye disorder"
],
[
"Eye disorder",
"{u} (Side Effect) is caused by {v} (C... | Bromfenac (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Prasugrel (Compound)
Bromfenac may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Prasugre... |
DB00938 | DB06707 | 455 | 584 | [
"DDInter1635",
"DDInter1060"
] | Salmeterol | Levonordefrin | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Levonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry. | Moderate | 1 | [
[
[
455,
24,
584
]
],
[
[
455,
24,
817
],
[
817,
40,
584
]
],
[
[
455,
24,
1354
],
[
1354,
1,
584
]
],
[
[
455,
24,
1148
],
[
1148,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonordefrin"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
],
[
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Dopamine and Dopamine (Compound) resembles Levonordefrin (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Droxidopa and Droxidopa (Compound) resembles Levonordefrin (Compound)
... |
DB00204 | DB00581 | 228 | 355 | [
"DDInter580",
"DDInter1018"
] | Dofetilide | Lactulose | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Moderate | 1 | [
[
[
228,
24,
355
]
],
[
[
228,
21,
28722
],
[
28722,
60,
355
]
],
[
[
228,
24,
286
],
[
286,
62,
355
]
],
[
[
228,
25,
79
],
[
79,
2... | [
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
]
],
[
[
"Dofetilide",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {... | Dofetilide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Lactulose (Compound)
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken wit... |
DB00026 | DB00631 | 1,184 | 372 | [
"DDInter94",
"DDInter405"
] | Anakinra | Clofarabine | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Moderate | 1 | [
[
[
1184,
24,
372
]
],
[
[
1184,
24,
1426
],
[
1426,
40,
372
]
],
[
[
1184,
25,
1064
],
[
1064,
25,
372
]
],
[
[
1184,
24,
329
],
[
329,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azacitidine"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Azacitidine and Azacitidine (Compound) resembles Clofarabine (Compound)
Anakinra may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken... |
DB00350 | DB01173 | 1,214 | 358 | [
"DDInter1226",
"DDInter1349"
] | Minoxidil | Orphenadrine | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. | Moderate | 1 | [
[
[
1214,
24,
358
]
],
[
[
1214,
24,
820
],
[
820,
63,
358
]
],
[
[
1214,
24,
1164
],
[
1164,
1,
358
]
],
[
[
1214,
24,
1405
],
[
1405,
... | [
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
... | Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Tr... |
DB00252 | DB11130 | 362 | 407 | [
"DDInter1460",
"DDInter1344"
] | Phenytoin | Opium | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
362,
24,
407
]
],
[
[
362,
24,
662
],
[
662,
24,
407
]
],
[
[
362,
25,
976
],
[
976,
24,
407
]
],
[
[
362,
23,
1347
],
[
1347,
2... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Phenytoin may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause... |
DB00013 | DB09030 | 1,255 | 840 | [
"DDInter1905",
"DDInter1945"
] | Urokinase | Vorapaxar | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Major | 2 | [
[
[
1255,
25,
840
]
],
[
[
1255,
23,
944
],
[
944,
62,
840
]
],
[
[
1255,
24,
383
],
[
383,
24,
840
]
],
[
[
1255,
24,
1496
],
[
1496,
... | [
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Urokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Urokinase may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Vorapaxar
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pento... |
DB01249 | DB03904 | 258 | 1,574 | [
"DDInter958",
"DDInter1903"
] | Iodixanol | Urea | Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. | A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. | Moderate | 1 | [
[
[
258,
24,
1574
]
],
[
[
258,
25,
1399
],
[
1399,
62,
1574
]
],
[
[
258,
40,
497
],
[
497,
24,
1574
]
],
[
[
258,
25,
1399
],
[
1399,
... | [
[
[
"Iodixanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Urea"
]
],
[
[
"Iodixanol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
],
[
"Lithium car... | Iodixanol may lead to a major life threatening interaction when taken with Lithium carbonate and Lithium carbonate may cause a minor interaction that can limit clinical effects when taken with Urea
Iodixanol (Compound) resembles Iohexol (Compound) and Iohexol may cause a moderate interaction that could exacerbate disea... |
DB00687 | DB01359 | 870 | 729 | [
"DDInter747",
"DDInter1417"
] | Fludrocortisone | Penbutolol | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Moderate | 1 | [
[
[
870,
24,
729
]
],
[
[
870,
63,
461
],
[
461,
1,
729
]
],
[
[
870,
24,
699
],
[
699,
40,
729
]
],
[
[
870,
21,
28698
],
[
28698,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol (Compound) resembles Penbutolol (Compound)
Fl... |
DB00349 | DB09085 | 902 | 587 | [
"DDInter401",
"DDInter1779"
] | Clobazam | Tetracaine | Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike old... | Tetracaine is an ester local anaesthetic currently available in combination with lidocaine as a cream and patch. | Moderate | 1 | [
[
[
902,
24,
587
]
],
[
[
902,
40,
686
],
[
686,
24,
587
]
],
[
[
902,
40,
686
],
[
686,
1,
1563
],
[
1563,
24,
587
]
],
[
[
902,
40... | [
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracaine"
]
],
[
[
"Clobazam",
"{u} (Compound) resembles {v} (Compound)",
"Oxazepam"
],
[
"Oxazepam",
"{u} may cause a moderate intera... | Clobazam (Compound) resembles Oxazepam (Compound) and Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Tetracaine
Clobazam (Compound) resembles Oxazepam (Compound) and Oxazepam (Compound) resembles Halazepam (Compound) and Halazepam may cause a moderate interaction that could exa... |
DB00365 | DB08865 | 839 | 1,593 | [
"DDInter842",
"DDInter448"
] | Grepafloxacin | Crizotinib | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
839,
25,
1593
]
],
[
[
839,
23,
450
],
[
450,
24,
1593
]
],
[
[
839,
24,
286
],
[
286,
63,
1593
]
],
[
[
839,
24,
455
],
[
455,
... | [
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cyclophosphamide"
],
[
"... | Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magne... |
DB00501 | DB01105 | 752 | 222 | [
"DDInter380",
"DDInter1665"
] | Cimetidine | Sibutramine | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Minor | 0 | [
[
[
752,
23,
222
]
],
[
[
752,
5,
11585
],
[
11585,
44,
222
]
],
[
[
752,
6,
8374
],
[
8374,
45,
222
]
],
[
[
752,
21,
28852
],
[
28852,
... | [
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
]
],
[
[
"Cimetidine",
"{u} (Compound) treats {v} (Disease)",
"obesity"
],
[
"obesity",
"{u} (Disease) is treated by {v} (C... | Cimetidine (Compound) treats obesity (Disease) and obesity (Disease) is treated by Sibutramine (Compound)
Cimetidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Cimetidine (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Sibutramine (Compound)
... |
DB00395 | DB00835 | 210 | 100 | [
"DDInter301",
"DDInter245"
] | Carisoprodol | Brompheniramine | Originally approved by the FDA in 1959 [FDA label], carisoprodol is a centrally acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and other medications. This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with b... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
210,
24,
100
]
],
[
[
210,
24,
832
],
[
832,
24,
100
]
],
[
[
210,
24,
649
],
[
649,
63,
100
]
],
[
[
210,
63,
1594
],
[
1594,
2... | [
[
[
"Carisoprodol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Carisoprodol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
... | Carisoprodol may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Carisoprodol may cause a moderate interaction that could exacerbate diseases when taken with Clof... |
DB00912 | DB09068 | 473 | 1,427 | [
"DDInter1581",
"DDInter1948"
] | Repaglinide | Vortioxetine | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Moderate | 1 | [
[
[
473,
24,
1427
]
],
[
[
473,
24,
1320
],
[
1320,
63,
1427
]
],
[
[
473,
24,
1220
],
[
1220,
24,
1427
]
],
[
[
473,
63,
1512
],
[
1512,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dex... |
DB06414 | DB08875 | 655 | 1,618 | [
"DDInter703",
"DDInter262"
] | Etravirine | Cabozantinib | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
655,
24,
1618
]
],
[
[
655,
24,
1135
],
[
1135,
62,
1618
]
],
[
[
655,
63,
112
],
[
112,
23,
1618
]
],
[
[
655,
63,
723
],
[
723,
... | [
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metro... |
DB01069 | DB06589 | 401 | 1,250 | [
"DDInter1533",
"DDInter1400"
] | Promethazine | Pazopanib | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
401,
24,
1250
]
],
[
[
401,
6,
4973
],
[
4973,
45,
1250
]
],
[
[
401,
21,
28680
],
[
28680,
60,
1250
]
],
[
[
401,
62,
1247
],
[
1247,... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Promethazine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)"... | Promethazine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Pazopanib (Compound)
Promethazine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Pazopanib (Compound)
Promethazine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamet... |
DB00108 | DB08871 | 1,066 | 36 | [
"DDInter1268",
"DDInter666"
] | Natalizumab | Eribulin | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Major | 2 | [
[
[
1066,
25,
36
]
],
[
[
1066,
24,
221
],
[
221,
63,
36
]
],
[
[
1066,
25,
1488
],
[
1488,
24,
36
]
],
[
[
1066,
64,
599
],
[
599,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
]
],
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde in... | Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) and Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Natalizumab may lead to a maj... |
DB01225 | DB08886 | 500 | 637 | [
"DDInter645",
"DDInter126"
] | Enoxaparin | Asparaginase Erwinia chrysanthemi | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Moderate | 1 | [
[
[
500,
24,
637
]
],
[
[
500,
64,
1479
],
[
1479,
24,
637
]
],
[
[
500,
25,
936
],
[
936,
24,
637
]
],
[
[
500,
25,
1421
],
[
1421,
... | [
[
[
"Enoxaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic aci... | Enoxaparin may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Enoxaparin may lead to a major life threatening interaction when taken with Cangrelo... |
DB00927 | DB11901 | 1,559 | 913 | [
"DDInter712",
"DDInter107"
] | Famotidine | Apalutamide | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
1559,
24,
913
]
],
[
[
1559,
62,
112
],
[
112,
23,
913
]
],
[
[
1559,
23,
1247
],
[
1247,
23,
913
]
],
[
[
1559,
63,
600
],
[
600,
... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Famotidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Famotidine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and... |
DB00213 | DB11703 | 837 | 405 | [
"DDInter1388",
"DDInter9"
] | Pantoprazole | Acalabrutinib | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
837,
25,
405
]
],
[
[
837,
24,
1297
],
[
1297,
63,
405
]
],
[
[
837,
24,
478
],
[
478,
24,
405
]
],
[
[
837,
63,
529
],
[
529,
2... | [
[
[
"Pantoprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
"O... | Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib ... |
DB00364 | DB00759 | 417 | 1,620 | [
"DDInter1717",
"DDInter1783"
] | Sucralfate | Tetracycline | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | Moderate | 1 | [
[
[
417,
24,
1620
]
],
[
[
417,
24,
1572
],
[
1572,
40,
1620
]
],
[
[
417,
63,
964
],
[
964,
40,
1620
]
],
[
[
417,
6,
1829
],
[
1829,
... | [
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
]
],
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
],
... | Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Tetracycline (Compound)
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline (Compound) resembles Tetracycli... |
DB00197 | DB00238 | 1,324 | 188 | [
"DDInter1881",
"DDInter1285"
] | Troglitazone | Nevirapine | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Moderate | 1 | [
[
[
1324,
24,
188
]
],
[
[
1324,
63,
168
],
[
168,
23,
188
]
],
[
[
1324,
23,
1101
],
[
1101,
62,
188
]
],
[
[
1324,
24,
473
],
[
473,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nevirapine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Nevirapine
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexaro... |
DB01246 | DB09237 | 820 | 1,586 | [
"DDInter45",
"DDInter1045"
] | Alimemazine | Levamlodipine | A phenothiazine derivative that is used as an antipruritic. | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Moderate | 1 | [
[
[
820,
24,
1586
]
],
[
[
820,
63,
1648
],
[
1648,
24,
1586
]
],
[
[
820,
24,
549
],
[
549,
24,
1586
]
],
[
[
820,
25,
478
],
[
478,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
... | Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin ... |
DB00277 | DB01072 | 1,031 | 915 | [
"DDInter1791",
"DDInter129"
] | Theophylline | Atazanavir | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Minor | 0 | [
[
[
1031,
23,
915
]
],
[
[
1031,
6,
6017
],
[
6017,
45,
915
]
],
[
[
1031,
21,
28642
],
[
28642,
60,
915
]
],
[
[
1031,
63,
1684
],
[
1684... | [
[
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Atazanavir"
]
],
[
[
"Theophylline",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)... | Theophylline (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Atazanavir (Compound)
Theophylline (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Atazanavir (Compound)
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Caffeine and Caffeine... |
DB09263 | DB11348 | 1,436 | 1,065 | [
"DDInter1399",
"DDInter279"
] | Patiromer | Calcium Phosphate | Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. Each gram of patirome... | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
1436,
24,
1065
]
],
[
[
1436,
63,
1152
],
[
1152,
24,
1065
]
],
[
[
1436,
63,
1152
],
[
1152,
23,
819
],
[
819,
24,
1065
]
],
[
[
1436... | [
[
[
"Patiromer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Patiromer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
... | Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine... |
DB00668 | DB08882 | 874 | 1,281 | [
"DDInter652",
"DDInter1070"
] | Epinephrine | Linagliptin | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been avail... | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
874,
24,
1281
]
],
[
[
874,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
874,
6,
8374
],
[
8374,
45,
1281
]
],
[
[
874,
21,
29222
],
[
29222,
... | [
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[... | Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Epinephrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Epinephrine (Compound) causes Hypoglycaemia (Side Effect) and ... |
DB01238 | DB09039 | 673 | 1,670 | [
"DDInter118",
"DDInter629"
] | Aripiprazole | Eliglustat | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Moderate | 1 | [
[
[
673,
24,
1670
]
],
[
[
673,
63,
121
],
[
121,
24,
1670
]
],
[
[
673,
24,
594
],
[
594,
24,
1670
]
],
[
[
673,
24,
124
],
[
124,
... | [
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
... | Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and... |
DB08868 | DB09052 | 1,011 | 250 | [
"DDInter737",
"DDInter220"
] | Fingolimod | Blinatumomab | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Major | 2 | [
[
[
1011,
25,
250
]
],
[
[
1011,
24,
949
],
[
949,
63,
250
]
],
[
[
1011,
25,
1362
],
[
1362,
63,
250
]
],
[
[
1011,
64,
305
],
[
305,
... | [
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Blinatumomab"
]
],
[
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (forma... | Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Fingolimod... |
DB04861 | DB11827 | 1,592 | 433 | [
"DDInter1271",
"DDInter669"
] | Nebivolol | Ertugliflozin | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
1592,
24,
433
]
],
[
[
1592,
63,
959
],
[
959,
24,
433
]
],
[
[
1592,
24,
1455
],
[
1455,
24,
433
]
],
[
[
1592,
24,
1019
],
[
1019,
... | [
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid and Nitro... |
DB00245 | DB00372 | 357 | 999 | [
"DDInter181",
"DDInter1793"
] | Benzatropine | Thiethylperazine | Benztropine, with the chemical formula 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of Parkinson's disease. It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the dialkylpiperazines determined to be a dopamine upt... | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Moderate | 1 | [
[
[
357,
24,
999
]
],
[
[
357,
24,
1614
],
[
1614,
63,
999
]
],
[
[
357,
74,
352
],
[
352,
24,
999
]
],
[
[
357,
24,
1089
],
[
1089,
... | [
[
[
"Benzatropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Benzatropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
... | Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Benzatropine (Compound) resembles Trospium (Compound) and Benzatropine may cause a moderate interaction that... |
DB00500 | DB06715 | 24 | 239 | [
"DDInter1831",
"DDInter1500"
] | Tolmetin | Potassium Iodide | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Saturated solution of Potassium Iodide (SSKI) is used pharmaceutically for emergency use in patients experiencing acute symptoms of severe hyperthyroidism (also known as thyroid storm or thyrotoxic crisis). SSKI can also be used for radioiodine-contamination emergencies or in preparation of thyrotoxic patients for thyr... | Moderate | 1 | [
[
[
24,
24,
239
]
],
[
[
24,
21,
28809
],
[
28809,
60,
239
]
],
[
[
24,
40,
1263
],
[
1263,
24,
239
]
],
[
[
24,
24,
877
],
[
877,
6... | [
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium Iodide"
]
],
[
[
"Tolmetin",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is ca... | Tolmetin (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Potassium Iodide (Compound)
Tolmetin (Compound) resembles Bromfenac (Compound) and Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Potassium Iodide
Tolmetin may cause a moderate interact... |
DB01098 | DB11936 | 14 | 1,030 | [
"DDInter1622",
"DDInter176"
] | Rosuvastatin | Bempedoic acid | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events. Caused by genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and increase the risk of mortality from cardiovascular disease. About 1 in 4 patients, or 15 million Americans with el... | Moderate | 1 | [
[
[
14,
24,
1030
]
],
[
[
14,
63,
663
],
[
663,
24,
1030
]
],
[
[
14,
63,
467
],
[
467,
25,
1030
]
],
[
[
14,
63,
663
],
[
663,
24,
... | [
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bempedoic acid"
]
],
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]... | Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Simvastat... |
DB00348 | DB00446 | 254 | 597 | [
"DDInter1300",
"DDInter351"
] | Nitisinone | Chloramphenicol | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Moderate | 1 | [
[
[
254,
24,
597
]
],
[
[
254,
21,
28703
],
[
28703,
60,
597
]
],
[
[
254,
63,
1101
],
[
1101,
23,
597
]
],
[
[
254,
23,
307
],
[
307,
... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Nitisinone",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is c... | Nitisinone (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Chloramphenicol (Compound)
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Chlora... |
DB00353 | DB08912 | 588 | 1,040 | [
"DDInter1187",
"DDInter462"
] | Methylergometrine | Dabrafenib | A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed) | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
588,
24,
1040
]
],
[
[
588,
6,
8374
],
[
8374,
45,
1040
]
],
[
[
588,
7,
4333
],
[
4333,
46,
1040
]
],
[
[
588,
18,
4893
],
[
4893,
... | [
[
[
"Methylergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Methylergometrine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v... | Methylergometrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Methylergometrine (Compound) upregulates MEF2C (Gene) and MEF2C (Gene) is upregulated by Dabrafenib (Compound)
Methylergometrine (Compound) downregulates S100A13 (Gene) and S100A13 (Gene) is upregulated by Dabrafenib (C... |
DB01203 | DB09135 | 699 | 1,211 | [
"DDInter1255",
"DDInter967"
] | Nadolol | Ioxilan | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Moderate | 1 | [
[
[
699,
24,
1211
]
],
[
[
699,
40,
887
],
[
887,
24,
1211
]
],
[
[
699,
24,
1013
],
[
1013,
63,
1211
]
],
[
[
699,
24,
512
],
[
512,
... | [
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioxilan"
]
],
[
[
"Nadolol",
"{u} (Compound) resembles {v} (Compound)",
"Pindolol"
],
[
"Pindolol",
"{u} may cause a moderate interaction... | Nadolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid and Tyropanoic acid may cause a moderate interaction that could ex... |
DB00252 | DB01114 | 362 | 272 | [
"DDInter1460",
"DDInter362"
] | Phenytoin | Chlorpheniramine | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
362,
24,
272
]
],
[
[
362,
24,
849
],
[
849,
63,
272
]
],
[
[
362,
24,
128
],
[
128,
24,
272
]
],
[
[
362,
6,
8374
],
[
8374,
45... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramin... |
DB05578 | DB08816 | 330 | 578 | [
"DDInter1566",
"DDInter1802"
] | Ramucirumab | Ticagrelor | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Major | 2 | [
[
[
330,
25,
578
]
],
[
[
330,
64,
1578
],
[
1578,
24,
578
]
],
[
[
330,
63,
1039
],
[
1039,
24,
578
]
],
[
[
330,
24,
41
],
[
41,
6... | [
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
]
],
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} m... | Ramucirumab may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Ramucirumab may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine ... |
DB01069 | DB01242 | 401 | 1,237 | [
"DDInter1533",
"DDInter410"
] | Promethazine | Clomipramine | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
401,
24,
1237
]
],
[
[
401,
75,
684
],
[
684,
1,
1237
]
],
[
[
401,
1,
11275
],
[
11275,
40,
1237
]
],
[
[
401,
74,
1164
],
[
1164,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Promethazine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",... | Promethazine (Compound) resembles Thioridazine (Compound) and Promethazine may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Promethazine (Compound) resembles Chlorprothixene (Compound) and Chlorprothixene (Compound) resembles Clo... |
DB06616 | DB11793 | 594 | 738 | [
"DDInter224",
"DDInter1297"
] | Bosutinib | Niraparib | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
594,
24,
738
]
],
[
[
594,
63,
1213
],
[
1213,
24,
738
]
],
[
[
594,
24,
1033
],
[
1033,
63,
738
]
],
[
[
594,
24,
496
],
[
496,
... | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
... | Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib ma... |
DB00570 | DB01259 | 147 | 392 | [
"DDInter1936",
"DDInter1024"
] | Vinblastine | Lapatinib | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
147,
24,
392
]
],
[
[
147,
5,
11579
],
[
11579,
44,
392
]
],
[
[
147,
7,
2192
],
[
2192,
45,
392
]
],
[
[
147,
6,
4973
],
[
4973,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Vinblastine",
"{u} (Compound) treats {v} (Disease)",
"breast cancer"
],
[
"breast cancer",
"{u} (Disease) is tre... | Vinblastine (Compound) treats breast cancer (Disease) and breast cancer (Disease) is treated by Lapatinib (Compound)
Vinblastine (Compound) upregulates EGFR (Gene) and EGFR (Gene) is bound by Lapatinib (Compound)
Vinblastine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Vinblastine (Co... |
DB00795 | DB11828 | 50 | 1,406 | [
"DDInter1725",
"DDInter1281"
] | Sulfasalazine | Neratinib | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Moderate | 1 | [
[
[
50,
24,
1406
]
],
[
[
50,
63,
1252
],
[
1252,
24,
1406
]
],
[
[
50,
25,
1510
],
[
1510,
24,
1406
]
],
[
[
50,
24,
985
],
[
985,
... | [
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
... | Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Sulfasalazine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may c... |
DB00242 | DB08908 | 1,064 | 713 | [
"DDInter392",
"DDInter564"
] | Cladribine | Dimethyl fumarate | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Major | 2 | [
[
[
1064,
25,
713
]
],
[
[
1064,
36,
1083
],
[
1083,
24,
713
]
],
[
[
1064,
25,
4
],
[
4,
24,
713
]
],
[
[
1064,
64,
1394
],
[
1394,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Cladribine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Triflu... | Cladribine (Compound) resembles Trifluridine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Cladribine may lead to a major life threatening interact... |
DB00626 | DB09473 | 1,441 | 884 | [
"DDInter161",
"DDInter918"
] | Bacitracin | Indium In-111 oxyquinoline | Bacitracin is a combination of at least 9 bacitracins.[A955,A181952] 60-80% of commercially prepared bacitracin is bacitracin A. The bacillus that produces bacitracin was first isolated from a knee scrape in 1945 from the knee wound of a child named Margaret Tracy. Bacitracin was granted FDA approval on 29 July 1948.[A... | Indium In 111 oxyquinoline (oxine) is a diagnostic radiopharmaceutical intended for radiolabeling of autologous leukocytes. It is composed of a 3:1 saturated complex of In-111 isotope and oxyquinoline. Indium-111 decays by isomeric transition and electron capture to cadmium-111, emitting a gamma ray that can be detecte... | Moderate | 1 | [
[
[
1441,
24,
884
]
],
[
[
1441,
25,
1448
],
[
1448,
24,
884
]
],
[
[
1441,
24,
50
],
[
50,
24,
884
]
],
[
[
1441,
63,
91
],
[
91,
2... | [
[
[
"Bacitracin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indium In-111 oxyquinoline"
]
],
[
[
"Bacitracin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Streptomycin"
],
[... | Bacitracin may lead to a major life threatening interaction when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Indium In-111 oxyquinoline
Bacitracin may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine an... |
DB01128 | DB08875 | 918 | 1,618 | [
"DDInter204",
"DDInter262"
] | Bicalutamide | Cabozantinib | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
918,
25,
1618
]
],
[
[
918,
23,
1135
],
[
1135,
62,
1618
]
],
[
[
918,
62,
112
],
[
112,
23,
1618
]
],
[
[
918,
63,
723
],
[
723,
... | [
[
[
"Bicalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Bicalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxeg... | Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metro... |
DB01259 | DB09118 | 392 | 1,580 | [
"DDInter1024",
"DDInter1711"
] | Lapatinib | Stiripentol | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
392,
24,
1580
]
],
[
[
392,
24,
466
],
[
466,
62,
1580
]
],
[
[
392,
24,
1409
],
[
1409,
24,
1580
]
],
[
[
392,
24,
283
],
[
283,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Stiripentol
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaba... |
DB01191 | DB12364 | 1,039 | 1,421 | [
"DDInter518",
"DDInter200"
] | Dexfenfluramine | Betrixaban | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Moderate | 1 | [
[
[
1039,
24,
1421
]
],
[
[
1039,
64,
529
],
[
529,
24,
1421
]
],
[
[
1039,
25,
41
],
[
41,
24,
1421
]
],
[
[
1039,
24,
760
],
[
760,
... | [
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvoxamine"
],
[
... | Dexfenfluramine may lead to a major life threatening interaction when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Dexfenfluramine may lead to a major life threatening interaction when taken with Levomilnacipran and Levomilnacipran may... |
DB00014 | DB09043 | 521 | 135 | [
"DDInter839",
"DDInter36"
] | Goserelin | Albiglutide | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
521,
24,
135
]
],
[
[
521,
24,
1647
],
[
1647,
23,
135
]
],
[
[
521,
24,
519
],
[
519,
24,
135
]
],
[
[
521,
25,
695
],
[
695,
2... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
... | Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidon... |
DB00370 | DB01128 | 1,251 | 918 | [
"DDInter1230",
"DDInter204"
] | Mirtazapine | Bicalutamide | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Moderate | 1 | [
[
[
1251,
24,
918
]
],
[
[
1251,
24,
129
],
[
129,
40,
918
]
],
[
[
1251,
6,
8374
],
[
8374,
45,
918
]
],
[
[
1251,
21,
28642
],
[
28642,
... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
... | Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide (Compound) resembles Bicalutamide (Compound)
Mirtazapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bicalutamide (Compound)
Mirtazapine (Compound) causes Shock (Side Effect) and Sh... |
DB00218 | DB00704 | 1,176 | 267 | [
"DDInter1247",
"DDInter1263"
] | Moxifloxacin | Naltrexone | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Moderate | 1 | [
[
[
1176,
24,
267
]
],
[
[
1176,
21,
28695
],
[
28695,
60,
267
]
],
[
[
1176,
24,
850
],
[
850,
63,
267
]
],
[
[
1176,
25,
351
],
[
351,
... | [
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Moxifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspnoea"
],
[
"Dyspnoea",
"{u} (Side Effect) is ca... | Moxifloxacin (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Naltrexone (Compound)
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases whe... |
DB11730 | DB11791 | 351 | 785 | [
"DDInter1588",
"DDInter287"
] | Ribociclib | Capmatinib | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Moderate | 1 | [
[
[
351,
24,
785
]
],
[
[
351,
64,
1135
],
[
1135,
23,
785
]
],
[
[
351,
63,
1324
],
[
1324,
24,
785
]
],
[
[
351,
64,
868
],
[
868,
... | [
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",... | Ribociclib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Capmatinib
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause ... |
DB01142 | DB09100 | 1,264 | 320 | [
"DDInter593",
"DDInter1799"
] | Doxepin | Thyroid, porcine | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine (T4) used to supplement low or absent thyroid activity.[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891 but its use dates back as far as the 6th century. Thyro... | Moderate | 1 | [
[
[
1264,
24,
320
]
],
[
[
1264,
63,
73
],
[
73,
24,
320
]
],
[
[
1264,
25,
22
],
[
22,
24,
320
]
],
[
[
1264,
64,
1636
],
[
1636,
2... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Doxepin may lead to a major life threatening interaction when taken with Ephedrine and Ephedrine may cause ... |
DB06663 | DB06699 | 1,154 | 774 | [
"DDInter1398",
"DDInter493"
] | Pasireotide | Degarelix | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Major | 2 | [
[
[
1154,
25,
774
]
],
[
[
1154,
64,
521
],
[
521,
1,
774
]
],
[
[
1154,
21,
28703
],
[
28703,
60,
774
]
],
[
[
1154,
62,
112
],
[
112,
... | [
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Degarelix"
]
],
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} (C... | Pasireotide may lead to a major life threatening interaction when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Pasireotide (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Degarelix (Compound)
Pasireotide may cause a minor interaction that can limit clinic... |
DB01224 | DB06663 | 623 | 1,154 | [
"DDInter1553",
"DDInter1398"
] | Quetiapine | Pasireotide | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
623,
25,
1154
]
],
[
[
623,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
623,
62,
112
],
[
112,
23,
1154
]
],
[
[
623,
24,
1385
],
[
1385,
... | [
[
[
"Quetiapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Quetiapine",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused b... | Quetiapine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Quetiapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken... |
DB00816 | DB06707 | 1,674 | 584 | [
"DDInter1346",
"DDInter1060"
] | Orciprenaline | Levonordefrin | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Levonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry. | Moderate | 1 | [
[
[
1674,
24,
584
]
],
[
[
1674,
24,
817
],
[
817,
40,
584
]
],
[
[
1674,
24,
1354
],
[
1354,
1,
584
]
],
[
[
1674,
35,
1148
],
[
1148,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonordefrin"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
],
... | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Dopamine and Dopamine (Compound) resembles Levonordefrin (Compound)
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Droxidopa and Droxidopa (Compound) resembles Levonordefrin (Comp... |
DB00418 | DB09074 | 536 | 1,362 | [
"DDInter1650",
"DDInter1327"
] | Secobarbital | Olaparib | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
536,
24,
1362
]
],
[
[
536,
24,
1478
],
[
1478,
24,
1362
]
],
[
[
536,
63,
353
],
[
353,
24,
1362
]
],
[
[
536,
62,
168
],
[
168,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Gris... |
DB01001 | DB11796 | 688 | 1,612 | [
"DDInter1632",
"DDInter786"
] | Salbutamol | Fostemsavir | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the... | Moderate | 1 | [
[
[
688,
24,
1612
]
],
[
[
688,
63,
1324
],
[
1324,
23,
1612
]
],
[
[
688,
23,
1220
],
[
1220,
23,
1612
]
],
[
[
688,
62,
112
],
[
112,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[... | Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and De... |
DB01229 | DB11952 | 973 | 800 | [
"DDInter1377",
"DDInter612"
] | Paclitaxel | Duvelisib | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
973,
24,
800
]
],
[
[
973,
24,
310
],
[
310,
24,
800
]
],
[
[
973,
63,
467
],
[
467,
24,
800
]
],
[
[
973,
24,
1476
],
[
1476,
6... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simv... |
DB00365 | DB04272 | 839 | 442 | [
"DDInter842",
"DDInter390"
] | Grepafloxacin | Citric acid | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium-chelating ability. Citric acid is one of the active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020. ... | Moderate | 1 | [
[
[
839,
24,
442
]
],
[
[
839,
24,
115
],
[
115,
64,
442
]
],
[
[
839,
23,
37
],
[
37,
62,
1176
],
[
1176,
24,
442
]
],
[
[
839,
24,... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citric acid"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
... | Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide and Aluminum hydroxide may lead to a major life threatening interaction when taken with Citric acid
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Lomustine and L... |
DB00889 | DB00983 | 1,133 | 480 | [
"DDInter840",
"DDInter776"
] | Granisetron | Formoterol | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
1133,
24,
480
]
],
[
[
1133,
24,
1148
],
[
1148,
63,
480
]
],
[
[
1133,
6,
12523
],
[
12523,
45,
480
]
],
[
[
1133,
18,
10375
],
[
103... | [
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
... | Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Granisetron (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Formoterol (Compound)
Granisetron ... |
DB06595 | DB11978 | 1,491 | 124 | [
"DDInter1214",
"DDInter822"
] | Midostaurin | Glasdegib | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
1491,
24,
124
]
],
[
[
1491,
23,
1135
],
[
1135,
23,
124
]
],
[
[
1491,
62,
1247
],
[
1247,
23,
124
]
],
[
[
1491,
24,
327
],
[
327,
... | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Midostaurin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Midostaurin may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Midostaurin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfame... |
DB01124 | DB12267 | 1,411 | 1,476 | [
"DDInter1828",
"DDInter233"
] | Tolbutamide | Brigatinib | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1411,
24,
1476
]
],
[
[
1411,
24,
1206
],
[
1206,
23,
1476
]
],
[
[
1411,
63,
168
],
[
168,
23,
1476
]
],
[
[
1411,
63,
629
],
[
629,
... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemfibrozil"
],
[... | Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Gemfibrozil and Gemfibrozil may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bort... |
DB06210 | DB11644 | 72 | 647 | [
"DDInter631",
"DDInter1737"
] | Eltrombopag | Tafamidis | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019. | Moderate | 1 | [
[
[
72,
24,
647
]
],
[
[
72,
63,
1419
],
[
1419,
24,
647
]
],
[
[
72,
63,
1419
],
[
1419,
24,
613
],
[
613,
24,
647
]
],
[
[
72,
63,... | [
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tafamidis"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
... | Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Tafamidis
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib ma... |
DB00675 | DB01159 | 888 | 419 | [
"DDInter1744",
"DDInter854"
] | Tamoxifen | Halothane | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Moderate | 1 | [
[
[
888,
24,
419
]
],
[
[
888,
6,
8374
],
[
8374,
45,
419
]
],
[
[
888,
23,
256
],
[
256,
62,
419
]
],
[
[
888,
23,
112
],
[
112,
23... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halothane"
]
],
[
[
"Tamoxifen",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Tamoxifen (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Halothane (Compound)
Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Halothane
Tamoxifen may cause a minor ... |
DB00710 | DB12015 | 1,199 | 1,033 | [
"DDInter897",
"DDInter53"
] | Ibandronate | Alpelisib | Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid].[A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis.[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatm... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
1199,
24,
1033
]
],
[
[
1199,
25,
629
],
[
629,
24,
1033
]
],
[
[
1199,
40,
1485
],
[
1485,
24,
1033
]
],
[
[
1199,
24,
50
],
[
50,
... | [
[
[
"Ibandronate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Ibandronate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus"... | Ibandronate may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Ibandronate (Compound) resembles Alendronic acid (Compound) and Alendronic acid may cause a moderate interaction that could exace... |
DB00950 | DB08938 | 1,413 | 1,384 | [
"DDInter732",
"DDInter1112"
] | Fexofenadine | Magaldrate | Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamin... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Moderate | 1 | [
[
[
1413,
24,
1384
]
],
[
[
1413,
63,
954
],
[
954,
23,
1384
]
],
[
[
1413,
24,
1468
],
[
1468,
23,
1384
]
],
[
[
1413,
24,
72
],
[
72,
... | [
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[... | Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatin... |
DB04868 | DB09104 | 478 | 286 | [
"DDInter1293",
"DDInter1118"
] | Nilotinib | Magnesium hydroxide | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
478,
24,
286
]
],
[
[
478,
63,
481
],
[
481,
23,
286
]
],
[
[
478,
64,
820
],
[
820,
23,
286
]
],
[
[
478,
24,
263
],
[
263,
23,... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
],
... | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Nilotinib may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cau... |
DB00342 | DB08816 | 1,181 | 578 | [
"DDInter1770",
"DDInter1802"
] | Terfenadine | Ticagrelor | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
1181,
24,
578
]
],
[
[
1181,
25,
17
],
[
17,
23,
578
]
],
[
[
1181,
25,
1011
],
[
1011,
62,
578
]
],
[
[
1181,
25,
723
],
[
723,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
],
[
"Sotalol",
... | Terfenadine may lead to a major life threatening interaction when taken with Sotalol and Sotalol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Terfenadine may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a minor interaction t... |
DB00039 | DB00970 | 1,253 | 0 | [
"DDInter1380",
"DDInter466"
] | Palifermin | Dactinomycin | Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004. | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also d... | Moderate | 1 | [
[
[
1253,
24,
0
]
],
[
[
1253,
24,
1532
],
[
1532,
63,
0
]
],
[
[
1253,
24,
611
],
[
611,
24,
0
]
],
[
[
1253,
24,
770
],
[
770,
64,... | [
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dactinomycin"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
... | Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine and Dac... |
DB05239 | DB09237 | 866 | 1,586 | [
"DDInter425",
"DDInter1045"
] | Cobimetinib | Levamlodipine | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Moderate | 1 | [
[
[
866,
24,
1586
]
],
[
[
866,
24,
578
],
[
578,
23,
1586
]
],
[
[
866,
63,
478
],
[
478,
24,
1586
]
],
[
[
866,
24,
1297
],
[
1297,
... | [
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
... | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Levamlodipine
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilo... |
DB06700 | DB09030 | 643 | 840 | [
"DDInter511",
"DDInter1945"
] | Desvenlafaxine | Vorapaxar | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of ad... | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Moderate | 1 | [
[
[
643,
24,
840
]
],
[
[
643,
63,
885
],
[
885,
24,
840
]
],
[
[
643,
64,
1039
],
[
1039,
24,
840
]
],
[
[
643,
24,
578
],
[
578,
2... | [
[
[
"Desvenlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
]
],
[
[
"Desvenlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],... | Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Desvenlafaxine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfe... |
DB00496 | DB01409 | 194 | 1,415 | [
"DDInter480",
"DDInter1815"
] | Darifenacin | Tiotropium | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L... | Moderate | 1 | [
[
[
194,
24,
1415
]
],
[
[
194,
6,
4304
],
[
4304,
45,
1415
]
],
[
[
194,
21,
29187
],
[
29187,
60,
1415
]
],
[
[
194,
24,
752
],
[
752,
... | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Darifenacin",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compound)",... | Darifenacin (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Tiotropium (Compound)
Darifenacin (Compound) causes Rhinitis (Side Effect) and Rhinitis (Side Effect) is caused by Tiotropium (Compound)
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimet... |
DB00678 | DB08820 | 240 | 1,478 | [
"DDInter1095",
"DDInter997"
] | Losartan | Ivacaftor | Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough simila... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
240,
24,
1478
]
],
[
[
240,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
240,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
240,
24,
617
],
[
617,
... | [
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Losartan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Losartan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Losartan (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Losartan may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may... |
DB01259 | DB04844 | 392 | 843 | [
"DDInter1024",
"DDInter1778"
] | Lapatinib | Tetrabenazine | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
392,
24,
843
]
],
[
[
392,
62,
479
],
[
479,
40,
843
]
],
[
[
392,
18,
3106
],
[
3106,
57,
843
]
],
[
[
392,
21,
28698
],
[
28698,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Lapatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
... | Lapatinib may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Lapatinib (Compound) downregulates DNAJA3 (Gene) and DNAJA3 (Gene) is downregulated by Tetrabenazine (Compound)
Lapatinib (Compound) causes Insomnia (Side Effect)... |
DB00026 | DB12674 | 1,184 | 975 | [
"DDInter94",
"DDInter1105"
] | Anakinra | Lurbinectedin | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Moderate | 1 | [
[
[
1184,
24,
975
]
],
[
[
1184,
24,
1488
],
[
1488,
24,
975
]
],
[
[
1184,
25,
980
],
[
980,
24,
975
]
],
[
[
1184,
63,
305
],
[
305,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Anakinra may lead to a major life threatening interaction when taken with Tocilizumab and Tocilizumab may cau... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.